Table 3 Treatment-related non-haematological adverse eventsa during and after cycle one occurring in ⩾5% of patients for all cohorts combined (N=33)
Cycle 1, n (%) | After cycle 1, n (%) | |||
|---|---|---|---|---|
Adverse event | All grades | Grade 3 | All grades | Grade 3 |
Fatigue | 11 (33) | 0 | 10 (30) | 1 (3) |
Nausea | 10 (30) | 0 | 5 (15) | 1 (3) |
Diarrhoea | 6 (18) | 0 | 10 (30) | 0 |
Constipation | 4 (12) | 0 | 3 (9) | 0 |
Rash | 4 (12) | 0 | 2 (6) | 0 |
Vomiting | 2 (6) | 0 | 2 (6) | 1 (3) |
Peripheral oedema | 3 (9) | 0 | 2 (6) | 0 |
Dyspnea | 3 (9) | 0 | 1 (3) | 0 |
Anorexia | 1 (3) | 0 | 3 (9) | 0 |
Pyrexia | 1 (3) | 0 | 2 (6) | 0 |
Epistaxis | 0 | 0 | 4 (12) | 0 |
Flatulence | 0 | 0 | 3 (9) | 0 |
Mucosal inflammation | 0 | 0 | 3 (9) | 0 |
Chills | 0 | 0 | 2 (6) | 0 |
Muscular weakness | 0 | 0 | 2 (6) | 0 |
Cough | 0 | 0 | 2 (6) | 0 |
Alopecia | 0 | 0 | 2 (6) | 0 |
